Medical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectant
FDA classifies foam or gel chemical sterilant/high level disinfectants as Class II medical devices, requiring special controls. This does not directly affect cosmetics under MoCRA but may impact businesses that also manufacture or distribute such disinfectants used in cosmetic facilities.
Aforeworn detected this change in the Cosmetics & Personal-Care (MoCRA) space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Cosmetic businesses that also manufacture or distribute foam or gel chemical sterilant/high level disinfectants for medical device use. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective June 26, 2026. Compliance expected immediately for new products; existing products may need to comply by a later date (check FDA guidance).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Cosmetics & Personal-Care (MoCRA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA classified these products as Class II medical devices, subject to special controls (e.g., performance testing, labeling).
Who it affects
Cosmetic businesses that also manufacture or distribute foam or gel chemical sterilant/high level disinfectants for medical device use.
What you must do
If you manufacture or distribute these products, ensure compliance with Class II special controls (e.g., 510(k) clearance, labeling requirements).
Deadline
Effective June 26, 2026. Compliance expected immediately for new products; existing products may need to comply by a later date (check FDA guidance).
Never miss a change like this again
Aforeworn watches Cosmetics & Personal-Care (MoCRA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Cosmetics & Personal-Care (MoCRA)
- FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
- FDA Grants Seventh Approval under the National Priority Voucher Pilot Program
- FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
- FDA Expands AI Capabilities and Completes Data Platform Consolidation
- FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection